BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Oncology News, Insights, Stories by OncoDaily - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Oncology News, Insights, Stories by OncoDaily
X-ORIGINAL-URL:https://oncodaily.com
X-WR-CALDESC:Events for Oncology News, Insights, Stories by OncoDaily
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Hong_Kong
BEGIN:STANDARD
TZOFFSETFROM:+0800
TZOFFSETTO:+0800
TZNAME:HKT
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Halifax
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20240310T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20241103T050000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20250309T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20251102T050000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20260308T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20261101T050000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Africa/Cairo
BEGIN:DAYLIGHT
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:EEST
DTSTART:20240425T220000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:EET
DTSTART:20241031T210000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:EEST
DTSTART:20250424T220000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:EET
DTSTART:20251030T210000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:EEST
DTSTART:20260423T220000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:EET
DTSTART:20261029T210000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Denver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20240310T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20241103T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20250309T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20251102T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20260308T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20261101T080000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Asia/Hong_Kong:20250115T140000
DTEND;TZID=Asia/Hong_Kong:20250115T160000
DTSTAMP:20260504T021803
CREATED:20250106T184225Z
LAST-MODIFIED:20250608T082104Z
UID:10000114-1736949600-1736956800@oncodaily.com
SUMMARY:2025 CACA-OncoDaily-SPCC Cancer Summit: Bridging Continents
DESCRIPTION:The Cancer Summit\, organized by the China Anti-Cancer Association (CACA)\, OncoDaily\, Sharing Progress in Cancer Care (SPCC)\, and the World Association for Integrative Oncology (WAIO)\, will take place on January 15\, 2025 via Zoom and will feature simultaneous translation in English and Chinese. \nThe summit will be held at the following times: \n\nChina Standard Time: 02:00-04:00pm\nUS EST: 01:00-03:00am\nCentral European Time: 07:00-09:00am\n\nThe event highlights the crucial rule of collaboration in tackling the current challenges faced in oncology. \nRead more about the event here.
URL:https://oncodaily.com/event/caca-oncodaily-spcc-cancer-summit218610
ATTACH;FMTTYPE=image/jpeg:https://oncodaily.com/pub/uploads/2025/01/5.1-2025-CACA-Oncodaily-SPCC-Cancer-Summit-Poster.jpg
ORGANIZER;CN="the China Anti-Cancer Association (CACA)":MAILTO:intl@caca.org.cn
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20250121T130000
DTEND;TZID=America/Halifax:20250121T143000
DTSTAMP:20260504T021803
CREATED:20250111T200927Z
LAST-MODIFIED:20250608T082110Z
UID:10000116-1737464400-1737469800@oncodaily.com
SUMMARY:Exploring a New Generation of Patient-Centric Cancer Clinical Trials by AACR
DESCRIPTION:Exploring a New Generation of Patient-Centric Cancer Clinical Trials by AACR will be held on January 21\, 2025\, Virtually. \nThe forum will explore the new generation of patient-centric cancer clinical trials\, focusing on how advancements in cancer research will reshape the clinical trial process. As more people are expected to survive and live beyond cancer\, largely due to clinical trials\, the conference will highlight the ongoing transformation in trial design. The emphasis will be on creating more efficient\, inclusive\, and patient-focused trials that prioritize patient needs and preferences. This shift will be critical in ensuring broader access to innovative treatments and improving overall patient outcomes. \nThe upcoming session will feature a group of esteemed experts in the field of cancer research. Jan Tomlinson from the University of California\, San Francisco\, will share insights from a patient advocate’s perspective on the clinical trial experience. Patricia M. LoRusso\, DO\, PhD (HC)\, FAACR\, from Yale Cancer Center\, will discuss innovative clinical trial designs aimed at improving efficiency and inclusivity. David A. Tuveson\, MD\, PhD\, FAACR\, from CSHL Cancer Center\, will highlight the Cancer Therapeutics Initiative\, which focuses on translating basic research into clinical applications. Laura van ‘t Veer\, PhD\, from the University of California\, San Francisco\, will present on the second-generation design of the I-SPY 2 trial\, driving advancements in precision medicine. These experts will cover a broad range of topics\, all geared toward advancing cancer clinical trials and patient care. \nRegister Now!
URL:https://oncodaily.com/event/221654
ATTACH;FMTTYPE=image/jpeg:https://oncodaily.com/pub/uploads/2025/01/1736108582473-e1736625939487.jpg
ORGANIZER;CN="American Association for Cancer Research":MAILTO:aacr@aacr.org
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250123
DTEND;VALUE=DATE:20250124
DTSTAMP:20260504T021803
CREATED:20250123T185013Z
LAST-MODIFIED:20250608T082116Z
UID:10000121-1737590400-1737676799@oncodaily.com
SUMMARY:International BPDCN Day
DESCRIPTION:January 23rd of 2025 marks the International BPDCN Day. We unite to shed light on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)\, a rare and aggressive hematologic malignancy that often remains underdiagnosed due to its rarity and complex presentation. \nWhat do we know about BPDCN?\nIn 2008\, BPDCN was recognized by the WHO as a distinct entity and separately listed in the group of acute myeloid leukemias and related precursor neoplasms. BPDCN predominantly affects the skin\, bone marrow\, and lymph nodes\, posing significant diagnostic and therapeutic challenges. Despite advances in hematology\, much remains to be understood about its pathogenesis\, optimal treatment strategies\, and long-term outcomes. Greater awareness and focused research are critical to improving the prognosis for patients worldwide. \nAt present\, there is no consensus on the optimal treatment of BPDCN. The majority of patients receive multi-agent chemotherapy with AML or ALL treatment regimens\, while a few patients undergo allogeneic hematopoietic stem cell transplantation (HSCT). Different novel and innovative therapies are in development to target surface molecules in BPDCN. However\, patients are still in need of better treatments and the optimal therapy for the disease remains to be determined. \nWhat can we do for patients diagnosed with BPDCN?\nUnfortunately\, projects devoted to this mission are not many either. The BPDCN International Registry is one of them\, aimed in building a large database of patients to investigate the characteristics and outcomes of the disease with different treatment regimens\, evaluate prognostic factors\, and generate data-based prospective treatment recommendations. \nLet’s unite on International BPDCN Day to amplify our collective efforts\, inspire new collaborations\, and give hope to patients and their families. Together\, we can make a meaningful difference in the fight against this disease.
URL:https://oncodaily.com/event/bpdcn-230151
LOCATION:WorldWide
ATTACH;FMTTYPE=image/jpeg:https://oncodaily.com/pub/uploads/2025/01/IMG_6943-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Cairo:20250123T000000
DTEND;TZID=Africa/Cairo:20250124T000000
DTSTAMP:20260504T021803
CREATED:20241219T143049Z
LAST-MODIFIED:20250608T082123Z
UID:10000098-1737590400-1737676800@oncodaily.com
SUMMARY:The 17th BGICC 2025
DESCRIPTION:The 17th BGICC 2025 (Breast\, Gynecological and Immuno-oncology International Cancer Conference) is a premier event in the field of oncology\, widely recognized as the largest and most prestigious cancer conference in both Africa and the Middle East. Scheduled to take place from January 23-24\, 2025\, at the Hilton Heliopolis Hotel in Cairo\, Egypt\, this conference serves as a hub for oncology professionals\, researchers\, and clinicians to gather and share cutting-edge knowledge and advancements in cancer care and treatment. \nThe conference will feature a comprehensive agenda that includes high-level lectures\, interactive workshops\, and specialized courses\, providing participants with an opportunity to delve into the latest research and clinical practices in breast cancer\, gynecological oncology\, and immuno-oncology. The event aims to bridge the gap between scientific discovery and clinical application\, offering insights into innovative therapies\, emerging treatment protocols\, and the evolving landscape of cancer care. \nThe 17th BGICC 2025 is set to be led by some of the most esteemed experts in oncology. The course will be directed by Prof. Manal El Mahdy from Ain Shams University\, with Prof. Rouba Ali-Fehmi from the University of Michigan serving as the course co-director. These renowned experts will guide participants through discussions and sessions on the latest breakthroughs in cancer research and treatment. \nBy attending BGICC 2025\, participants will not only gain valuable knowledge but also network with leaders in the oncology field\, share ideas\, and collaborate on global efforts to advance cancer treatment and patient care. The conference promises to be an exciting and impactful event that will shape the future of oncology in the region and beyond. \nThe Abstract Submission Closes at December 29th. \nFor Registration\, visit here.
URL:https://oncodaily.com/event/200357
LOCATION:the Hilton Heliopolis Hotel in Cairo\, Egypt\, El-Orouba\, Sheraton Al Matar\, El Nozha\, Cairo Governorate\, El Nozha\, Cairo\, Al\, Egypt
ATTACH;FMTTYPE=image/jpeg:https://oncodaily.com/pub/uploads/2024/12/Untitled-1755.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20250123T073000
DTEND;TZID=America/Denver:20250125T160000
DTSTAMP:20260504T021803
CREATED:20241007T155451Z
LAST-MODIFIED:20250713T084159Z
UID:10000014-1737617400-1737820800@oncodaily.com
SUMMARY:ASCO Gastrointestinal Cancers Symposium 2025
DESCRIPTION:The ASCO Gastrointestinal Cancers 2025 Symposium\, happening on January 23-25 in Moscone West\, San Francisco\, will bring together top experts in gastrointestinal oncology. Attendees can look forward to insightful keynote talks\, engaging panel discussions\, and the latest research on treatments and diagnostics for gastrointestinal cancers. \nThe event will also showcase poster presentations from emerging researchers\, offering great networking opportunities for everyone involved. \nThe Co-Organizers of the symposium are the American Society of Clinical Oncology\, the American Gastroenterological Association\, the American Society for Radiation Oncology and the Society of Surgical Oncology. \nThis symposium is a must-attend for anyone interested in the latest trends and innovations in the field\, as it will play a vital role in shaping the future of patient care in gastrointestinal oncology. \nRegister here.
URL:https://oncodaily.com/event/159556
LOCATION:Moscone West\, 800 Howard Street\, San Francisco\, United States
ATTACH;FMTTYPE=image/jpeg:https://oncodaily.com/pub/uploads/2024/10/asco.jpg
ORGANIZER;CN="American Society of Clinical Oncology":MAILTO:https://asco.org/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20250123T150000
DTEND;TZID=America/Halifax:20250123T170000
DTSTAMP:20260504T021803
CREATED:20241217T191048Z
LAST-MODIFIED:20250608T082132Z
UID:10000107-1737644400-1737651600@oncodaily.com
SUMMARY:HEAL webinar series on the health impacts of per- and polyfluoroalkyl substances
DESCRIPTION:HEAL webinar series on the health impacts of per- and polyfluoroalkyl substances will be held on 23 January 2024 at 15:00 CET. \nThe HEAL Virtual Webinar Series on PFAS and Human Health is a crucial initiative aimed at raising awareness about the health impacts of PFAS (Per- and Polyfluoroalkyl Substances). These chemicals\, widely used in consumer products\, have been linked to various health concerns\, including immune system disruption\, cancer\, and developmental issues. The series invites leading experts to discuss the health effects of PFAS exposure\, with each webinar focusing on different aspects of this growing issue. The series aims to inform the public and policymakers on the importance of addressing PFAS contamination and its long-term health implications. \nOrganized in partnership with the Association of European Cancer Leagues (ECL)\, this session will explore the links between PFAS and cancer\, considering the evaluation from the International Agency for Research on Cancer (IARC) and supporting epidemiological studies. The webinar will feature Dr. Tony Fletcher\, an Associate Professor at the London School of Hygiene and Tropical Medicine\, who has led research on PFAS exposure in communities in Ronneby\, Sweden\, and Veneto\, Italy. His research has contributed to understanding the carcinogenic potential of PFAS and its widespread health risks. \nThis webinar is part of a broader effort to educate and raise awareness about the dangers of PFAS exposure. Recordings of previous webinars\, including topics on the immune system and the effects of early-life exposure to PFAS\, will also be made available for those who wish to catch up on the ongoing discussion. The series serves as a critical platform for sharing the latest scientific findings and fostering discussions on how to mitigate the health risks associated with these harmful substances. \nRegistration is Open.
URL:https://oncodaily.com/event/207626
ATTACH;FMTTYPE=image/png:https://oncodaily.com/pub/uploads/2024/12/PFAS-Webinar-series-X-7.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Cairo:20250124T080000
DTEND;TZID=Africa/Cairo:20250125T203000
DTSTAMP:20260504T021803
CREATED:20250121T201151Z
LAST-MODIFIED:20250608T082141Z
UID:10000120-1737705600-1737837000@oncodaily.com
SUMMARY:The Breathe for Hope Conference
DESCRIPTION:The Breathe for Hope Conference is a pioneering event that combines the expertise of the Oncothoracic International Cancer Association (OnTIC) and the Onco-Bronchology International Conference (OncoBroncho). Scheduled to take place on 24-25 January 2025 at the prestigious Hilton Cairo Heliopolis\, this conference is designed to bring together leading professionals\, researchers\, and clinicians from across the globe to explore the latest advancements in oncology and lung health. The event will serve as a platform to share cutting-edge research\, discuss innovative treatment strategies\, and collaborate on future directions in the fight against lung cancer and other thoracic diseases. \nAttendees can expect to engage in thought-provoking discussions\, attend workshops\, and hear from experts on various topics\, from the latest molecular treatments to groundbreaking techniques in bronchoscopy and thoracic surgery. This conference represents an exciting opportunity to be at the forefront of cancer research and treatment\, as experts come together to push the boundaries of what’s possible in improving patient outcomes. \nRegisteration is Open for the Event.
URL:https://oncodaily.com/event/228785
LOCATION:the Hilton Heliopolis Hotel in Cairo\, Egypt\, El-Orouba\, Sheraton Al Matar\, El Nozha\, Cairo Governorate\, El Nozha\, Cairo\, Al\, Egypt
ATTACH;FMTTYPE=image/jpeg:https://oncodaily.com/pub/uploads/2025/01/WhatsApp-Image-2025-01-21-at-11.22.43.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20250126T180000
DTEND;TZID=America/Denver:20250129T130000
DTSTAMP:20260504T021803
CREATED:20241008T195536Z
LAST-MODIFIED:20250608T082146Z
UID:10000023-1737914400-1738155600@oncodaily.com
SUMMARY:AACR Conference on Translating Targeted Therapies in Combination with Radiotherapy
DESCRIPTION:The AACR Special Conference in Cancer Research: Translating Targeted Therapies in Combination with Radiotherapy\, will be taking place at the Hilton San Diego Bayfront\, on January 26-29\, 2025. This conference will explore the future of radiation therapy\, focusing on innovative areas like heavy ion therapy\, FLASH radiation\, and the synergy between radiation and targeted therapies. \nThis event is organized by the American Association for Cancer Research. It’s an exciting opportunity to learn how these advancements can personalize cancer treatment and improve long-term outcomes for patients. \nDon’t miss your chance to be part of this transformative event in San Diego!
URL:https://oncodaily.com/event/160878
LOCATION:Hilton San Diego Bayfront\, 1 Park Blvd\, San Diego\, CA\, 92101\, United States
ATTACH;FMTTYPE=image/jpeg:https://oncodaily.com/pub/uploads/2024/10/GZDiek2X0AA4etg.jpg
ORGANIZER;CN="American Association for Cancer Research":MAILTO:aacr@aacr.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20250129T180000
DTEND;TZID=America/Halifax:20250129T210000
DTSTAMP:20260504T021803
CREATED:20250113T170456Z
LAST-MODIFIED:20250608T082151Z
UID:10000117-1738173600-1738184400@oncodaily.com
SUMMARY:Outlook for the HR+/HER2- MBC treatment landscape in 2025 and beyond by SPCC
DESCRIPTION:Outlook for the HR+/HER2- MBC treatment landscape in 2025 and beyond by SPCC will be held at January 29th\, 2025 at 6 pm. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThe Outlook for the HR+/HER2- MBC Treatment Landscape in 2025 and Beyond Live Webinar will focus on the latest advancements and future directions in treating HR+ HER2- metastatic breast cancer (MBC). Experts will review recent clinical trial data\, discuss the current treatment landscape\, and explore the role of novel therapies\, including CDK4/6 inhibitors\, PI3K inhibitors\, and targeted therapies. The evolving landscape will also include next-generation treatments that could reshape patient care in the coming years. \nBiomarker testing plays a central role in guiding treatment decisions for HR+ HER2- MBC\, and the conference will cover how genomic tests and liquid biopsies\, such as ctDNA\, can help personalize therapies. A discussion will also take place on the balance between biomarker-driven therapies versus non-biomarker approaches\, addressing when and how each strategy should be utilized in clinical practice. \nThe conference will also focus on optimizing treatment sequencing based on clinical characteristics such as tumor burden\, mutational status\, and patient performance. Esteemed speakers include Dr. Martin Miguel (Hospital General Universitario Gregorio Marañón\, Spain)\, Dr. Neven Patrick (Universitaire Ziekenhuizen Leuven\, Belgium)\, and Dr. Joyce O’Shaughnessy (Baylor-Sammons Cancer Center\, USA)\, who will share their expertise on the latest research and treatment strategies for HR+ HER2- MBC.
URL:https://oncodaily.com/event/222894
ATTACH;FMTTYPE=image/jpeg:https://oncodaily.com/pub/uploads/2025/01/WhatsApp-Image-2025-01-12-at-16.20.43.jpeg
ORGANIZER;CN="Sharing Progress in Cancer Care":MAILTO:info@spcc.net
END:VEVENT
END:VCALENDAR